Clinical Rheumatology

, Volume 35, Issue 1, pp 151–158 | Cite as

Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis

  • Shaobo Zhang
  • Yibao Zhang
  • Peng Liu
  • Wei Zhang
  • Jing-lin Ma
  • Jing Wang
Original Article


The aim is to study the efficacy and safety of etoricoxib in the treatment of acute gout, as compared with non-steroidal anti-inflammatory drugs (NSAIDs). We conducted a computerized search of electronic databases: PubMed, EMBASE, Web of Science, China Biology Medicine disc, and Cochrane Library. The search terms were as follows: gout arthritis, tophus, etoricoxib, indometacin naproxen, diclofenac, and NSAIDs. Articles were searched from 1983 until August 2014. A manual search of peer-reviewed English documents was performed by cross-checking the bibliographies of selected studies. These trials reported pain relief as the primary outcome. Tenderness, swelling, patients’ global assessments of response to treatment, and investigators’ global assessments of response to treatment were reported as the secondary outcomes. All adverse events were recorded for safety assessment. Six trials including 851 patients were identified. Both etoricoxib and NSAIDs had an effect on inflammation and analgesia. Compared with indometacin and diclofenac, etoricoxib had a lower incidence of adverse events. Etoricoxib 120 mg administered orally once daily has the same efficacy on acute gout as indometacin and diclofenac. Etoricoxib is tolerated better by patients than NSAIDs such as indometacin and diclofenac.


Acute gouty arthritis Cyclooxygenase-2 Diclofenac Etoricoxib Indometacin NSAID 



Non-steroidal anti-inflammatory drugs


Randomized controlled trials


Adverse events


Experimental group


Control group


Sample size


Relative risk


Weighted mean difference


  1. 1.
    Harris MD, Siegel LB, Alloway JA (1999) Gout and hyperuricemia. Am Fam Physician 59(4):925–934PubMedGoogle Scholar
  2. 2.
    Fam AG (1998) Gout in the elderly. Clinical presentation and treatment. Drugs Aging 13(3):229–243PubMedCrossRefGoogle Scholar
  3. 3.
    Garcia-Mendez S, Beas-Ixtlahuac E, Hernandez-Cuevas C et al (2012) Female gout: age and duration of the disease determine clinical presentation. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 18(5):242–245Google Scholar
  4. 4.
    So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28. doi:10.1186/ar2143 PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Buckley TJ (1996) Radiologic features of gout. Am Fam Physician 54(4):1232–1238PubMedGoogle Scholar
  6. 6.
    Terkeltaub RA, Ginsberg MH (1988) The inflammatory reaction to crystals. Rheum Dis Clin N Am 14(2):353–364Google Scholar
  7. 7.
    Wortmann RL (1998) Effective management of gout: an analogy. Am J Med 105(6):513–514PubMedCrossRefGoogle Scholar
  8. 8.
    Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 64(10):1447–1461CrossRefGoogle Scholar
  9. 9.
    Schumacher HR Jr, Boice JA, Daikh DI et al (2002) Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ (Clin Res ed) 324(7352):1488–1492CrossRefGoogle Scholar
  10. 10.
    Willburger RE, Mysler E, Derbot J, Jung T et al (2007) Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxford, England) 46(7):1126–1132CrossRefGoogle Scholar
  11. 11.
    Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F et al (2012) Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol 39(9):1859–1866PubMedCrossRefGoogle Scholar
  12. 12.
    Riendeau D, Percival MD, Brideau C, Charleson S et al (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296(2):558–566PubMedGoogle Scholar
  13. 13.
    Leung AT, Malmstrom K, Gallacher AE, Sarembock B et al (2002) Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 18(2):49–58PubMedCrossRefGoogle Scholar
  14. 14.
    Donnelly MT, Hawkey CJ (1997) Review article: COX-II inhibitors—a new generation of safer NSAIDs? Aliment Pharmacol Ther 11(2):227–236PubMedCrossRefGoogle Scholar
  15. 15.
    Peura DA (2002) Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med 69(Suppl 1):Si31–Si39PubMedGoogle Scholar
  16. 16.
    Scheiman JM (2002) Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 69(Suppl 1):Si40–Si46PubMedGoogle Scholar
  17. 17.
    Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20(3):895–900PubMedCrossRefGoogle Scholar
  18. 18.
    Rubin BR, Burton R, Navarra S, Antigua J et al (2004) Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 50(2):598–606PubMedCrossRefGoogle Scholar
  19. 19.
    Li T, Chen SL, Dai Q, Han XH et al (2013) Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial. Chin Med J 126(10):1867–1871PubMedGoogle Scholar
  20. 20.
    Lu JL (2014) Clinical efficacy of etoricoxib in the treatment of acute gouty arthritis. Pract Pharm Clin Remedies 17(4):451–453Google Scholar
  21. 21.
    Ye Q, Du PF, Wang ZZ et al (2010) Effect of etoricoxib on acute gout. Clin Educ Gen Pract 8(4):391–393Google Scholar
  22. 22.
    Guo M, Cheng ZF, Hu YH et al (2014) Evaluation of efficacy of COX-2 inhibitors in the treatment of patients with acute gouty arthritis. Prog Mod Biomed 14(29):5747–5750Google Scholar
  23. 23.
    Pouliot M, James MJ, McColl SR, Naccache PH, Cleland LG (1998) Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 91(5):1769–1776PubMedGoogle Scholar
  24. 24.
    Cochrane DJ, Jarvis B, Keating GM (2002) Etoricoxib. Drugs 62(18):2637–2651, discussion 2652–2633 PubMedCrossRefGoogle Scholar
  25. 25.
    Schumacher HR Jr (2004) Management strategies for osteoarthritis, ankylosing spondylitis, and gouty arthritis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 10(3 Suppl):S18–S25Google Scholar
  26. 26.
    Chen YF, Jobanputra P, Barton P, Bryan S et al (2008) Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess (Winchester, England) 12(11):1–278Google Scholar
  27. 27.
    Lories RJ (2012) Etoricoxib and the treatment of ankylosing spondylitis. Expert Opin Drug Metab Toxicol 8(12):1599–1608PubMedCrossRefGoogle Scholar
  28. 28.
    Leclercq P, Malaise MG (2004) Etoricoxib (arcoxia). Rev Med Liege 59(5):345–349PubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2015

Authors and Affiliations

  • Shaobo Zhang
    • 1
  • Yibao Zhang
    • 1
  • Peng Liu
    • 1
  • Wei Zhang
    • 1
  • Jing-lin Ma
    • 1
  • Jing Wang
    • 1
    • 2
  1. 1.Key Laboratory of Orthopedics of Gansu Province, The Second Hospital of Lanzhou UniversityLanzhou UniversityLanzhouPeople’s Republic of China
  2. 2.Department of OrthopedicsThe Second Hospital of Lanzhou UniversityLanzhouPeople’s Republic of China

Personalised recommendations